These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 28383355)

  • 21. Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients.
    Farag S; Verheijen RB; Martijn Kerst J; Cats A; Huitema AD; Steeghs N
    Clin Pharmacokinet; 2017 Mar; 56(3):287-292. PubMed ID: 27435281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physiologically based pharmacokinetic modeling of imatinib and N-desmethyl imatinib for drug-drug interaction predictions.
    Loer HLH; Kovar C; Rüdesheim S; Marok FZ; Fuhr LM; Selzer D; Schwab M; Lehr T
    CPT Pharmacometrics Syst Pharmacol; 2024 Jun; 13(6):926-940. PubMed ID: 38482980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors.
    Verboom MC; Kloth JSL; Swen JJ; Sleijfer S; Reyners AKL; Steeghs N; Mathijssen RHJ; Gelderblom H; Guchelaar HJ
    Pharmacogenomics J; 2019 Oct; 19(5):473-479. PubMed ID: 30713339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Skin lesions in patients treated with imatinib mesylate: a 5-year prospective study.
    Paolino G; Didona D; Clerico R; Corsetti P; Ambrifi M; Bottoni U; Calvieri S
    Cutis; 2016 Jun; 97(6):E12-6. PubMed ID: 27416091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PDGFRα promoter polymorphisms and expression patterns influence risk of development of imatinib-induced thrombocytopenia in chronic myeloid leukemia: A study from India.
    Guru SA; Mir R; Bhat M; Najar I; Zuberi M; Sumi M; Masroor M; Gupta N; Saxena A
    Tumour Biol; 2017 Oct; 39(10):1010428317713857. PubMed ID: 29019285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of ADME gene polymorphisms on imatinib disposition: results from a population pharmacokinetic study in chronic myeloid leukaemia.
    Shriyan B; Mehta P; Patil A; Jadhav S; Kumar S; Puri AS; Govalkar R; Krishnamurthy MN; Punatar S; Gokarn A; Khattry N; Gota V
    Eur J Clin Pharmacol; 2022 Aug; 78(8):1321-1330. PubMed ID: 35652931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
    Hochhaus A
    Ann Hematol; 2004; 83 Suppl 1():S65-6. PubMed ID: 15124676
    [No Abstract]   [Full Text] [Related]  

  • 28. [Association between genetic polymorphisms and variation of imatinib pharmacokinetics in gastrointestinal stromal tumors].
    Qiu H; Zhuang W; Wang X; Huang M; Zhou Z
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1031-1034. PubMed ID: 28900995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacology and pharmacokinetics of imatinib in pediatric patients.
    Suttorp M; Bornhäuser M; Metzler M; Millot F; Schleyer E
    Expert Rev Clin Pharmacol; 2018 Mar; 11(3):219-231. PubMed ID: 29076384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia.
    Skoglund K; Richter J; Olsson-Strömberg U; Bergquist J; Aluthgedara W; Ubhayasekera SJ; Vikingsson S; Svedberg A; Söderlund S; Sandstedt A; Johnsson A; Aagesen J; Alsenhed J; Hägg S; Peterson C; Lotfi K; Gréen H
    Ther Drug Monit; 2016 Apr; 38(2):230-8. PubMed ID: 26693810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation Between N-Demethyl Imatinib Trough Concentration and Serious Adverse Reactions in Patients with Gastrointestinal Stromal Tumors: A Retrospective Cohort Study.
    Liu M; Guo T; Ma Z; Du L; Hou J; Tian Y; Meng M; Chen X
    Ther Drug Monit; 2024 Jun; 46(3):344-350. PubMed ID: 38176855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian study.
    Van Obbergh F; Knoops L; Devos T; Beguin Y; Graux C; Benghiat F; Kargar-Samani K; Bauwens D; Efira A; Dubois C; Springael C; Montfort L; Connerotte T; Capron A; Delannoy A; Wallemacq P
    Clin Biochem; 2017 May; 50(7-8):452-454. PubMed ID: 28017570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?
    Zhuang W; Xie JD; Zhou S; Zhou ZW; Zhou Y; Sun XW; Yuan XH; Huang M; Liu S; Xin S; Su QB; Qiu HB; Wang XD
    Cancer Med; 2018 Feb; 7(2):317-324. PubMed ID: 29316372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia.
    Ben Hassine I; Gharbi H; Soltani I; Ben Hadj Othman H; Farrah A; Amouri H; Teber M; Ghedira H; Ben Youssef Y; Safra I; Abbes S; Menif S
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):829-839. PubMed ID: 28836054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia.
    Salimizand H; Amini S; Abdi M; Ghaderi B; Azadi NA
    Tumour Biol; 2016 Jan; 37(1):791-8. PubMed ID: 26250462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical pharmacokinetics of imatinib mesylate.
    Levêque D; Maloisel F
    In Vivo; 2005; 19(1):77-84. PubMed ID: 15796158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment.
    Jaruskova M; Curik N; Hercog R; Polivkova V; Motlova E; Benes V; Klamova H; Pecherkova P; Belohlavkova P; Vrbacky F; Machova Polakova K
    J Exp Clin Cancer Res; 2017 Apr; 36(1):55. PubMed ID: 28420426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia.
    Takahashi N; Miura M; Scott SA; Kagaya H; Kameoka Y; Tagawa H; Saitoh H; Fujishima N; Yoshioka T; Hirokawa M; Sawada K
    J Hum Genet; 2010 Nov; 55(11):731-7. PubMed ID: 20720558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of physiologically based pharmacokinetic modeling to understand real-world outcomes in patients receiving imatinib for chronic myeloid leukemia.
    Adattini JA; Adiwidjaja J; Gross AS; McLachlan AJ
    Pharmacol Res Perspect; 2023 Aug; 11(4):e01082. PubMed ID: 37417254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A lower dosage of imatinib in patients with gastrointestinal stromal tumors with toxicity of the treatment.
    Yin Y; Xiang J; Tang S; Chen J; Yu Q; Zhang B
    Medicine (Baltimore); 2016 Dec; 95(49):e5488. PubMed ID: 27930532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.